Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102365 | 1.00 | CYP3A4 (0.59) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL11821082 | 0.90 | SHBG (0.68) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL10940211 | 0.89 | CYP19A1 (0.62) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL10940216 | 0.89 | CYP19A1 (0.62) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL2251175 | 0.89 | SRD5A2 (0.61) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL216171 | 0.89 | SRD5A2 (0.61) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL8340076 | 0.85 | SHBG (0.48) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL8340073 | 0.85 | SHBG (0.48) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL11231672 | 0.84 | CYP3A4 (0.52) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL2540247 | 0.82 | CYP3A4 (0.63) | CYP3A4TSHRTHPOHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265328-B2 | C-19 steroids for specific therapeutic uses | PROCIMA GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| EP-2949361-B1 | C-19 STEROIDS FOR TREATING CELLULITE | ATHENION AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| EP-2060261-B1 | C-19 steroids for cosmetic uses | ATHENION AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2949361-A1 | C-19 steroids for treating cellulite | Curadis GmbH (DE) | 2015-12-02 | — | — | EP | disclosed |
| EP-2500062-B1 | C-19 steroids for specific therapeutic uses | CURADIS GMBH (DE) | 2015-08-12 | — | — | EP | disclosed |
| EP-2564900-B1 | C-19 steroids for therapeutic uses | CURADIS GMBH (DE) | 2015-04-22 | — | — | EP | disclosed |
| EP-2060300-B1 | C-19 steroids for therapeutic uses | CURADIS GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| EP-2564900-A1 | C-19 steroids for therapeutic uses | Procima GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2500062-A2 | C-19 steroids for specific therapeutic uses | Procima GmbH (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-8258123-B2 | C-19 steroids for cosmetic and further uses | ERLACOS GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| EP-2260903-A1 | C-19 steroids for therapeutic uses | Procima GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100256102-A1 | C-19 STEROIDS FOR COSMETIC AND FURTHER USES | ERLACOS GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2009062683-A1 | C-19 STEROIDS FOR THERAPEUTIC USES | ERLACOS GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2060300-A1 | C-19 steroids for therapeutic uses | ErlaCos GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060261-A1 | C-19 steroids for cosmetic and further uses | ErlaCos GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265328-B2 | C-19 steroids for specific therapeutic uses | AR, CYP17A1, SHBG | CYP3A4 113/4885TSHR 743/4885THPO 4776/4885 |
| US-20100256102-A1 | C-19 STEROIDS FOR COSMETIC AND FURTHER USES | HSD17B7, HSD17B13, HSD3B2 | CYP3A4 78/4885TSHR 215/4885THPO 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.